Ustekinumab
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4159 publications
Effectiveness of ustekinumab and improvement in real-world work productivity and associated indirect costs in patients with moderate-severe Crohn's disease in the United States of America.
Journal: Current medical research and opinion
Published: January 19, 2026
A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence.
Journal: The American journal of case reports
Published: January 16, 2026
Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication.
Journal: Scandinavian journal of gastroenterology
Published: January 16, 2026
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.
Journal: JAMA dermatology
Published: January 07, 2026
Generalised granuloma annulare following ustekinumab therapy for palmoplantar psoriasis.
Journal: BMJ case reports
Published: December 31, 2025
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study.
Journal: Journal of Crohn's & colitis
Published: December 27, 2025
Research Progress on Exclusive Enteral Nutrition Combined with Biologics in the Treatment of Adult Crohn's Disease.
Journal: Journal of Crohn's & colitis
Published: December 26, 2025
Predicting self-administered biologic nonadherence in Medicare fee-for-service beneficiaries with inflammatory bowel disease using machine learning models.
Journal: Journal of managed care & specialty pharmacy
Published: December 24, 2025
Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study.
Journal: Journal of Crohn's & colitis
Published: December 15, 2025
HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.
Journal: Journal of Crohn's & colitis
Published: December 13, 2025
High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study.
Journal: Scandinavian journal of gastroenterology
Published: December 08, 2025
Last Updated: 02/24/2026